



NEWS RELEASE

LITHOGOLD™ APPROVED!

November 3, 2006 (Woodstock, Georgia) – TRT, LLC today announced that its LithoGold™ device has received substantial equivalency approval from the US Food and Drug Administration (FDA) to be marketed in the U.S. as an extracorporeal shockwave lithotripsy device intended to fragment urinary stones in the kidney and ureter. The LithoGold electrohydraulic system represents the latest in technological advancements in the field of lithotripsy, setting the *new Gold Standard* for lithotripsy treatment.

(Lithotripsy is the use of shock waves to break kidney and ureter stones into fragments small enough to pass through the urinary tract.)



The LithoGold utilizes exclusive patented technology in its Smartrode “intelligent” electrode. The Smartrode is able to self-adjust to ensure that the distance between the electrode tips remains constant throughout the life of the electrode, thus producing the most consistent shockwave in the industry.

The LithoGold is also portable and modular and offers the largest treatment area and deepest penetration depth of any lithotripter on the market. *During the FDA clinical study, the LithoGold demonstrated a remarkable success rate of 95%.*

“This is a major achievement for our company and we are delighted to be able to provide this technology to the American public. We also look forward to bringing news of more exciting milestones in the future,” stated John Warlick, TRT president.

About TRT

TRT is a leading-edge health care company that believes in “doing well by doing good.” Our state-of-the-art medical devices utilize MultiWave™ technology (a combination of heat, electromagnetic, acoustic, and light energies) to provide non-invasive and minimally invasive treatment for numerous pathological conditions, including chronic wounds, multiple periodontal applications, pseudoarthrosis and other avascular conditions of the bone, and ischemic heart disease. TRT is headquartered in suburban Atlanta, Georgia from which we operate our urology division, Shockwave Technical Service, and our cardiac subsidiary, Cardiac Regeneration Technologies. Production of our devices is handled by TRT’s manufacturing subsidiary, MTS Europe GmbH, located in Lake Constance, Germany. Our devices are currently CE approved and distributed in approximately 20 countries throughout North America, Europe, Asia, Africa and South America. For more information, please visit the company’s website at www.trtllc.com.

Contact information: TRT, Julie Dodd, (770) 966-1315 or jdodd@trtllc.com